Topical treatment of acne using a compounded medication based on clindamycin

Abstract

Clindamycin, a lincosamide antibiotic, is widely used in the treatment of bacterial infections. It acts by inhibiting protein synthesis inbacteria, primarily targeting the peptidyl transferase centre in the bacterial ribosome. It exhibits bacteriostatic activity, inhibiting bacterialgrowth, and at higher doses, it can be bactericidal. In the treatment of acne vulgaris, clindamycin not only exerts direct antibacterialeffects but also possesses anti-inflammatory and immunomodulatory properties. It reduces the growth of Cutibacterium acnes and inhibitsthe production of proteins and lipases, which contribute to skin inflammation. Clindamycin also enhances bacterial opsonization andphagocytosis and reduces neutrophil chemotaxis. Combination therapy with benzoyl peroxide can help minimize antibiotic resistance.Topical clindamycin, often in combination with benzoyl peroxide or retinoids, is recommended in treatment for mild to moderate papulopustularacne. In hidradenitis suppurativa clindamycin improves disease control and reduces cutaneous lesions, particularly superficialones like papules and pustules. Various topical preparations containing clindamycin are available commercially, including gels, lotions, andcombination products with tretinoin or benzoyl peroxide. Additionally, the registration of clindamycin as a pharmaceutical raw materialallows for compounding personalized formulations, providing a cost-effective alternative. Compounded medications can be tailored toindividual patient needs and increase treatment effectiveness.